| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2195510 | Molecular and Cellular Endocrinology | 2016 | 9 Pages |
•LV-Notch1-shRNA led to a significant decline of clonogenicity and migration in human endometrial stem cells in vitro.•In vivo, LV-Notch1-shRNA inhibit the volume and weight of endometriotic lesions in murine models.•Specific inhibition of Notch1 alters endometriotic tissue growth and progression.
The recent characterization of stem/progenitor cells in the endometrium has shed new light for pathogenesis of endometriosis. The present study was undertaken to investigate the role of Notch1, known as a cell fate regulator, in the mechanism of endometriosis. Influence of Notch1 on endometrial stem cells proliferation and migration was evaluated by knocking down Notch1 expression using shRNA. Furthermore, human endometrial stromal and epithelial stem cells with or without LV-Notch1-shRNA were injected into the peritoneal cavity of nude mice, to assess the in vivo effects of a specific antagonist of Notch1 on the progression of endometriosis. The results showed that LV-Notch1-shRNA led to a significant decline of clonogenicity and migration in human endometrial stem cells in vitro, as well as the size of endometriotic lesions in murine models. These data provide evidence that specific inhibition of Notch1 alters endometriotic tissue growth and progression, and may represent a promising potential therapeutic avenue.
